➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKinsey
Colorcon
Express Scripts
Boehringer Ingelheim

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 6,250,469

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,250,469
Title: Formulations for protection of peg-interferon alpha conjugates
Abstract:The present invention provides formulations that prevent loss and damage of PEG-interferon alpha conjugates during and following lyophilization. The formulations of the present invention protect PEG-interferon alpha conjugates from loss and degradation during the lyophilization process, as well as degradation during subsequent storage. The formulations of the present invention are suitable for protection of PEG-interferon alpha conjugates from various types of degradation, including, but not limited to loss of biological activity and changes in the degree and/or nature of conjugation. A preferred PEG-interferon alpha conjugate protectable in the formulations of the present invention is an interferon alpha-2b-polyethylene glycol (12,000) conjugate.
Inventor(s): Kline; Douglas (New York, NY)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:09/703,581
Patent Claims:see list of patent claims

Details for Patent 6,250,469

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering PEGINTRON peginterferon alfa-2b VIAL 103949 001 2001-01-19   Start Trial Schering Corporation (Kenilworth, NJ) 2018-03-26 RX company
Schering PEGINTRON peginterferon alfa-2b VIAL 103949 002 2001-01-19   Start Trial Schering Corporation (Kenilworth, NJ) 2018-03-26 RX company
Schering PEGINTRON peginterferon alfa-2b VIAL 103949 003 2001-01-19   Start Trial Schering Corporation (Kenilworth, NJ) 2018-03-26 RX company
Schering PEGINTRON peginterferon alfa-2b VIAL 103949 004 2001-01-19   Start Trial Schering Corporation (Kenilworth, NJ) 2018-03-26 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKinsey
Express Scripts
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.